Wilhelmus Cm Groenhuysen - 27 Feb 2024 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role: Chief Operating Officer
Signature: Steven Robbins, as attorney in fact for Groenhuysen, Wilhelmus CM
Issuer symbol: NVCR
Transactions as of: 27 Feb 2024
Net transactions value: +$1,901,811
Form type: 4
Filing time: 29 Feb 2024, 16:28:11 UTC
Previous filing: 05 Sep 2023
Next filing: 05 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVCR	Ordinary Shares	Award	$38.07	+3	+0%	$12.69	209,828	31 Dec 2023	Direct	F1, F2
transaction	NVCR	Ordinary Shares	Award	$766,654	+47,034	+22%	$16.30	256,862	27 Feb 2024	Direct	F3
transaction	NVCR	Ordinary Shares	Sale	$37,177	-2,303	-0.9%	$16.14	254,559	28 Feb 2024	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVCR	Stock Options (Right to buy)	Award	$1,172,296	+71,920		$16.30	71,920	27 Feb 2024	Ordinary Shares	71,920	$16.30	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2023 through December 31, 2023. This transaction is also exempt under Rule 16b-3(c).
F2	In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2023.
F3	Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
F4	Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F5	Options to buy 71,920 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.